Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and ph...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2014-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/760 |
| _version_ | 1827962226878709760 |
|---|---|
| author | A. I. Sinopalnikov |
| author_facet | A. I. Sinopalnikov |
| author_sort | A. I. Sinopalnikov |
| collection | DOAJ |
| description | The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and pharmacodynamic profiles. The article tells about the results of several multicenter clinical trials of moxifloxacin and its use as a second-line therapy in tuberculosis of the respiratory tract. |
| first_indexed | 2024-04-09T16:39:21Z |
| format | Article |
| id | doaj.art-b16249ca4c4845348e0978d7dce631d1 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:39:21Z |
| publishDate | 2014-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b16249ca4c4845348e0978d7dce631d12023-04-23T06:56:45ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-01016364310.21518/2079-701X-2014-16-36-43760Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?A. I. Sinopalnikov0Russian Medical Academy of Postgraduate Education, MoscowThe article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and pharmacodynamic profiles. The article tells about the results of several multicenter clinical trials of moxifloxacin and its use as a second-line therapy in tuberculosis of the respiratory tract.https://www.med-sovet.pro/jour/article/view/760пневмониятуберкулезфторхинолонымоксифлоксацинpneumoniatuberculosisfluoroquinolonesofloxacin |
| spellingShingle | A. I. Sinopalnikov Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? Медицинский совет пневмония туберкулез фторхинолоны моксифлоксацин pneumonia tuberculosis fluoroquinolones ofloxacin |
| title | Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? |
| title_full | Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? |
| title_fullStr | Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? |
| title_full_unstemmed | Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? |
| title_short | Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? |
| title_sort | moxifloxacin in the treatment of community acquired pneumonia in adults what s new |
| topic | пневмония туберкулез фторхинолоны моксифлоксацин pneumonia tuberculosis fluoroquinolones ofloxacin |
| url | https://www.med-sovet.pro/jour/article/view/760 |
| work_keys_str_mv | AT aisinopalnikov moxifloxacininthetreatmentofcommunityacquiredpneumoniainadultswhatsnew |